Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Anthony W Tolcher, MD
South Texas Accelerated Research Therapeutics (START)
Principal Investigator - John Nemunaitis, MD
Mary Crowley Cancer Research Center
Principal Investigator - Jon M Rogers, MD
Azaya Therapeutics, Inc (Medical Monitor)
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mary Crowley Cancer Research Centers (mccrc)
Dallas, Texas, United States
- Cancer Therapy and Research Center (ctrc)
San Antonio, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Dec 2009
- Primary completion
- 31 Oct 2011
- Completion
- 31 Dec 2011
- Last update posted
- 6 Sept 2012
- Registered enrollment
- 29
- Registry id
- NCT01041235
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.